Key points
- Global revenue of US$90.2 million, a 28% increase from the previous period
- Gross profit increased 35% to US$44.1 million with gross margin improving to 48.9%
- Adjusted EBITDA loss of US$113.7 million, reflecting investments in commercial infrastructure
- Cash used in operations improved by 2% to US$116.0 million
- Net loss of US$149.6 million, slightly up from the previous period
Full summary
Saluda Medical, Inc. reported its preliminary final results for the fiscal year ended June 30, 2026. The company delivered global revenue of US$90.2 million, representing a 28% increase compared to the previous corresponding period. Revenue growth was driven by commercial execution in the United States and increased international demand. Gross profit increased by 35% to US$44.1 million, with gross margin improving to 48.9%. The improvement was due to lower product unit costs and operational efficiencies, partially offset by planned pricing impacts. Adjusted EBITDA loss was US$113.7 million, reflecting continued investment in commercial infrastructure. Cash used in operations improved by 2% to US$116.0 million, driven by revenue growth and improved gross profit. The net loss was US$149.6 million, slightly up from the previous period.